Published in Cancer Weekly, June 5th, 2001
D. Carbonelle and colleagues at ISOmer marine pharmacology lab in Nantes, France looked for clues in the genetics of an NSCLC cell line after treatment with methyl 4-methoxy-3-(3-methyl-2-butenoyl) benzoate (VT1), a chemical that induces cell cycle arrest at the G1 phase. The researchers used "differential display" to examine gene expression modifications after VT1 administration. Results from this assay would provide an idea...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.